Pharmaceutical Information |
Drug Name |
Remifentanil |
Drug ID |
BADD_D02430 |
Description |
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia. |
Indications and Usage |
For use during the induction and maintenance of general anesthesia. |
Marketing Status |
approved |
ATC Code |
N01AH06 |
DrugBank ID |
DB00899
|
KEGG ID |
D08473
|
MeSH ID |
D000077208
|
PubChem ID |
60815
|
TTD Drug ID |
D0T5OX
|
NDC Product Code |
Not Available |
UNII |
P10582JYYK
|
Synonyms |
Remifentanil | 3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic Acid Methyl Ester | Remifentanil Hydrochloride | Ultiva | Remifentanil Monohydrochloride | GI 87084B | GI87084B | GI-87084B |
|
Chemical Information |
Molecular Formula |
C20H28N2O5 |
CAS Registry Number |
132875-61-7 |
SMILES |
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|